• Regulatory NewsRegulatory News

    EC Previews Call to Set up Expert Panels for EU MDR/IVDR

    The European Commission (EC) said on Friday it will issue a call for applications to set up the expert panels for the premarket product evaluation consultation procedures provided under the EU’s medical device regulation (MDR) and in vitro diagnostic regulation (IVDR).   The EC is preparing to designate the new expert panels that will support the assessments for certain medical device classes and IVDs. The EU legislation obliges the EC to establish the expert panels ...
  • Regulatory NewsRegulatory News

    FDA Finalizes Guidance on Advertising and Promotional Material Submissions

    The US Food and Drug Administration (FDA) on Friday finalized guidance on the requirements and recommendations for submissions of promotional materials for prescription drugs and biological products, including the specific formats needed. The 37-page guidance, drafted in April 2015, describes the various types of voluntary submissions (e.g., launch and non-launch submissions of draft promotional materials for comments) and required submissions of promotional labeling an...
  • Regulatory NewsRegulatory News

    New Study Questions the Need for 12 Years of Market Exclusivity for Biologics

    The lengthy preclinical and clinical development necessary to bring a biologic to market has often been cited as one of the central reasons why biologics deserve 12 years of market exclusivity, or about five years more exclusivity than their small molecule counterparts. But a new study published Tuesday in Nature Biotechnology shows that the development time of a new biologic is generally about the same as the development time of a small molecule drug. The authors ...
  • ReconRecon

    Recon: FDA Rejects Daiichi Sankyo Blood Cancer Drug After Japanese Approval

    Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing.   In Focus: US FDA declines to approve Daiichi Sankyo's blood cancer treatment ( Reuters ) ( Endpoints ) FDA Expands Approval of Treatment for Cystic Fibrosis to Include Patients Ages 6 and Older ( FDA ) Merck CEO sees legal challenge if US adopts drug pricing based on other countries ( Reuters ) Merck says it has plenty in the pipe beyond Keytruda ( PMLive ) ICER says Nova...
  • Regulatory NewsRegulatory News

    FDA Releases 20 Years of Data on Medical Device Adverse Event Reports

    The US Food and Drug Administration (FDA) recently ended its Alternative Summary Reporting (ASR) program for medical devices, revoked the related exemptions and on Friday made available on its website all adverse event reports received under ASR exemptions from 1999 to 2019. FDA said it initially indended the ASR program to be for “specific well-known and well-characterized events associated with specific devices,” and that exempted submissions excluded events where the...
  • Regulatory NewsRegulatory News

    Paclitaxel-Coated Devices’ Late Mortality Signal Not Well Understood, FDA Panel Hears

    Following Wednesday’s debate on missing data necessary for paclitaxel-coated devices’ mortality assessments, the US Food and Drug Administration (FDA) advisory committee on Thursday offered recommendations on how to use what is in place to understand mortality signals.   Limited data on dose effect, toxicity and other potential factors have posed barriers for FDA and industry to achieve a complete understanding of paclitaxel- or drug-coated balloons (DCBs) and paclitaxe...
  • Regulatory NewsRegulatory News

    FDA’s OPDP Sends Third Untitled Letter of 2019

    The US Food and Drug Administration’s (FDA) Office of Prescription Drug Promotion (OPDP) recently released its third untitled letter of 2019 because of a direct-to-consumer video on Aclaris Therapeutics’ Eskata (hydrogen peroxide) that failed to adequately present the drug’s serious risks. The video, which originally aired on ABC’s The View last September, does not include “prominent, balancing risk information about Eskata,” OPDP said, noting that it is indicated f...
  • Regulatory NewsRegulatory News

    Iran, Argentina Join International Drug Regulators Group

    Regulators from Iran and Argentina have joined the International Pharmaceutical Regulators Programme (IPRP) as members, the IPRP announced following its third management committee meeting in Amsterdam earlier this month.   Less than a year after its first management committee meeting , IPRP’s membership has expanded to 26 members and two observers with the addition of Iran’s National Regulatory Authority (NRA) and Argentina’s National Administration of Drugs, Foods an...
  • Regulatory NewsRegulatory News
    TrackersTrackers

    FDA Advisory Committee Calendar

    Regulatory Focus is pleased to team with Tarius , a regulatory information services provider, to routinely offer information about upcoming FDA Scientific Advisory Committee (SAC) meetings for CDER, CBER, and the Office of the Commissioner. Upcoming Meetings   25 July – Arthritis Advisory Committee The committee will discuss a supplemental new drug application (sNDA) for nintedanib capsules (drug name OFEV), sponsored by Boehringer Ingelheim, for the trea...
  • ReconRecon

    Recon: Sanofi to Lay Off 466 in France and Germany in Shift to Cancer, Gene Therapies

    Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing.   In Focus: US Billions at Stake in Opioid Suits, But It's No Tobacco Windfall ( Bloomberg ) Boston drug-pricing watchdog group is ‘mouse that roared’ ( Boston Globe ) Cities, States Denied Committee Seats in Opioid Maker’s Bankruptcy ( WSJ ) Deadly Superbugs Win as Wall Street Flees Makers of Antibiotics ( Bloomberg ) FDA Lays Out Plan for Comparing New Opioids to Previous...
  • Regulatory NewsRegulatory News

    FDA Lays Out Plan for Comparing New Opioids to Previously Approved Ones

    The US Food and Drug Administration (FDA) on Thursday released new draft guidance on its benefit-risk assessment framework for opioids, outlining how the agency plans to compare the effectiveness and safety of new opioids with already approved opioids. The idea for a comparative approval standard, discussed by former FDA Commissioner Scott Gottlieb in March before a Senate committee, hinges on the fact that “FDA believes that there should be a premarket demonstration ...
  • Feature ArticlesFeature Articles

    Dietary Supplements and Public Safety: A Defense of DSHEA’s “Three-Legged Stool”

    This article discusses the passage of the Dietary Supplement Health and Education Act (DSHEA) in 1994 and its effects on the dietary supplement industry. The author addresses criticism of DSHEA and defends the intent and subsequent benefits of the legislation by identifying the “three legs of the stool” of the legislation—protection, safety and watchfulness.     Introduction   As the dietary supplement industry prepares to observe the 25th anniversary of the ...